ROIV · Roivant Sciences Ltd. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-20 | Pulik Richard |
CFO |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Common Shares
|
2,129 |
| 2026-09-20 | Humes Jennifer |
Chief Accounting Officer |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. |
Common Shares
|
3,880 |
| 2026-09-16 | Epperly Melissa B, |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-16 | Epperly Melissa B, |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | MOMTAZEE JAMES C |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-16 | Gold Daniel Allen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | Gold Daniel Allen |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-16 | Fitzgerald Meghan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | MANCHESTER KEITH S |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-16 | MANCHESTER KEITH S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | Fitzgerald Meghan |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-16 | Oren Ilan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | MOMTAZEE JAMES C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Stock Option (Right to Buy)
|
10,531 |
| 2026-09-16 | Oren Ilan |
Director |
Award↑
Filing footnotes — Common Shares (Direct)
Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Common Shares
|
5,054 |
| 2026-09-15 | Fitzgerald Meghan |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.28 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
Common Shares
|
400 |
| 2026-09-15 | Epperly Melissa B, |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
Common Shares
|
4,338 |
| 2026-09-15 | Fitzgerald Meghan |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
Common Shares
|
4,712 |
| 2026-09-15 | Epperly Melissa B, |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
Common Shares
|
600 |
| 2026-09-10 | Gold Daniel Allen |
Director |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
Common Shares
|
5,133 |
| 2026-09-10 | MOMTAZEE JAMES C |
Director |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
Common Shares
|
2,905 |
| 2026-09-10 | Oren Ilan |
Director |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
Common Shares
|
2,378 |
| 2026-09-10 | Epperly Melissa B, |
Director |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
Common Shares
|
2,179 |
| 2026-09-10 | Fitzgerald Meghan |
Director |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. |
Common Shares
|
1,743 |
| 2026-09-08 | Fitzgerald Meghan |
Director |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (Right to Buy)
|
20,000 |
| 2026-09-08 | Fitzgerald Meghan |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
Common Shares
|
20,000 |
| 2026-09-08 | Fitzgerald Meghan |
Director |
Convert↑
|
Common Shares
|
20,000 |
| 2026-08-28 | Venker Eric |
President & Immunovant CEO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
Common Shares
|
33,818 |
| 2026-08-28 | Venker Eric |
President & Immunovant CEO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
Common Shares
|
166,182 |
| 2026-08-28 | Venker Eric |
President & Immunovant CEO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (Right to Buy)
|
200,000 |
| 2026-08-28 | Venker Eric |
President & Immunovant CEO |
Convert↑
|
Common Shares
|
200,000 |
| 2026-08-21 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Stock Option (Right to Buy)
|
144,756 |
| 2026-08-21 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
144,756 |
| 2026-08-21 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
144,756 |
| 2026-08-20 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
17,519 |
| 2026-08-20 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Stock Option (Right to Buy)
|
17,519 |
| 2026-08-20 | Venker Eric |
President & Immunovant CEO |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Common Shares
|
13,909 |
| 2026-08-20 | Pulik Richard |
CFO |
Tax↓
Filing footnotes — Common Shares (Direct)
Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Includes Common Shares purchased under the Issuer's Employee Stock Purchase Plan. |
Common Shares
|
5,749 |
| 2026-08-20 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
17,519 |
| 2026-08-19 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Stock Option (Right to Buy)
|
172,899 |
| 2026-08-19 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
172,899 |
| 2026-08-19 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
172,899 |
| 2026-08-18 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
105,141 |
| 2026-08-18 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Common Shares (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Common Shares
|
136,942 |
| 2026-08-18 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.10 to $37.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
31,801 |
| 2026-08-18 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $37.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
105,141 |
| 2026-08-18 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
31,801 |
| 2026-08-17 | Sukhatme Mayukh |
Director, President & CIO |
Convert↑
|
Common Shares
|
284,707 |
| 2026-08-17 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Common Shares (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Common Shares
|
284,707 |
| 2026-08-17 | Sukhatme Mayukh |
Director, President & CIO |
Sell↓
Filing footnotes — Common Shares (Direct)
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
Common Shares
|
284,707 |
| 2026-08-14 | Sukhatme Mayukh |
Director, President & CIO |
Convert↓
Filing footnotes — Common Shares (Direct)
Award of stock options to purchase Common Shares that is fully vested. |
Common Shares
|
243,177 |